Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas
Science Signaling · 2024
DOI: 10.1126/scisignal.ado8303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, 2024. Verfasst von Matthew J Knarr und 5 weiteren Autor:innen. Beteiligte Einrichtung: Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, P…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Colforsin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
High-grade serous ovarian cancer (HGSOC) is one of the deadliest cancers for women, with a low survival rate, no early detection biomarkers, a high rate of recurrence, and few therapeutic options. Forskolin, an activator of cyclic AMP signaling, has several anticancer activities, including against HGSOC, but has limited use in vivo. Its water-soluble derivative, colforsin daropate, has the same mechanism of action as forskolin and is used to treat acute heart failure. Here, we investigated the potential of colforsin daropate as a treatment for HGSOC. We found that colforsin daropate induced cell cycle arrest and apoptosis in cultured HGSOC cells and spheroids but had negligible cytotoxicity in immortalized, nontumorigenic fallopian tube secretory cells and ovarian surface epithelial cells. Colforsin daropate also prevented HGSOC cells from invading ovarian surface epithelial cell layers in culture. In vivo, colforsin daropate reduced tumor growth, synergized with cisplatin (a standard chemotherapy in ovarian cancer care), and improved host survival in subcutaneous and intraperitoneal xenograft models. These antitumor effects of colforsin daropate were mediated in part by its reduction in the abundance and transcriptional activity of the oncoprotein c-MYC, which is often increased in HGSOC. Our findings demonstrate that colforsin daropate may be a promising therapeutic that could be combined with conventional therapies to treat HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Department of Translational Molecular Medicine, Saint John's Cancer Institute, Providence Health Services, Santa Monica, CA 90404, USA.
- Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI 48109, USA.
- Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
ORCID-Profile: Matthew J Knarr, Jamie Moon, Priyanka Rawat, Ronny Drapkin
Förderung
- NCI NIH HHS
Zitieren
APA
Knarr, M. J., Moon, J., Rawat, P., DiFeo, A., Hoon, D. S. B., & Drapkin, R. (2024). Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas. Science Signaling. https://doi.org/10.1126/scisignal.ado8303
Vancouver
Knarr MJ, Moon J, Rawat P, DiFeo A, Hoon DSB, Drapkin R. Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas. Science Signaling. 2024. doi:10.1126/scisignal.ado8303
BibTeX
@article{Knarr2024,
author = {Knarr, Matthew J and Moon, Jamie and Rawat, Priyanka and DiFeo, Analisa and Hoon, David S B and Drapkin, Ronny},
title = {Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas},
journal = {Science Signaling},
year = {2024},
doi = {10.1126/scisignal.ado8303}
}
EUVIMED